Navigation Links
OBS Medical's Visensia Patient Monitoring Technology Lowers Cost of Medical Malpractice Insurance

CARMEL, Ind., March 25 /PRNewswire/ -- OBS Medical has entered into an agreement with Beazley, a major Lloyds of London-based insurer of medical malpractice for US hospitals, for Beazley to provide insurance coverage at a reduced cost to hospitals that implement OBS's Visensia(R) patient monitoring technology to provide early warning of clinical crises.

Recognized by Frost and Sullivan as a 2008 North American Technology Innovation award winner, OBS Medical's Visensia hospital patient safety suite fuses data from multiple vital signs into a numerical index of a patient's wellness. When the predictive index reaches or surpasses a set threshold, an alert is triggered, indicating a patient may be at greater risk of deterioration.

Hospitals that use Visensia in a manner approved by Beazley's underwriters will be entitled to receive reimbursement of a portion of the premium paid for their medical malpractice insurance at the end of the policy period. The value of this return premium will vary, depending on the coverage provided. Return premiums of more than $100,000 have already been paid out to individual Beazley clients that have implemented agreed measures to improve the quality of patient care.

Beazley's Lloyd's syndicates, rated A by A.M. Best, insure US hospitals on a non-admitted or surplus lines basis and coverage can only be arranged through an accredited surplus lines broker.

OBS Medical's Chief Operating Officer Wayne Nethercutt said, "Clinical data have demonstrated the value of Visensia in providing early warning of potentially fatal deteriorations in patients' condition that might otherwise be missed. I am delighted that Beazley, a major insurer of hospitals' medical malpractice exposures with a track record of innovation, has recognized the benefits this can bring in reducing med mal claims."

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia(R)), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT(TM)), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

About Beazley Group

Beazley Group plc (BEZ.L) is the London-based parent company of global, specialist insurance businesses with operations in the UK, US, France, Germany, Singapore, Hong Kong and Australia. Beazley manages four Lloyd's syndicates: Syndicates 2623 and 623 underwrite a broad range of insurance and reinsurance business worldwide; Syndicate 3623 focuses on accident and health business; and 3622 is a dedicated life syndicate. In 2008, Beazley underwrote gross premiums of Euro 875.7 million. All Lloyd's syndicates are rated A by A.M. Best. In the US, our underwriters focus on writing specialist insurance products in the admitted market, backed by Beazley Insurance Company, Inc., an admitted property/casualty carrier in all 50 states; and surplus lines risks, backed by the Beazley syndicates at Lloyd's. Beazley Insurance Company, Inc. is rated A by A.M. Best.

We are market leaders in many of our chosen lines, which include professional indemnity, property, marine, reinsurance, accident and life, and political risks and contingency business.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hooper Holmes Concludes Sale of Medicals Direct
2. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
3. Comparison of obstetric outcomes between on-call and patients own obstetricians
4. Vision restoration therapy shown to improve brain activity in brain injured patients
5. Diabetes appears to increase risk of death for patients with acute coronary syndromes
6. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
7. Restricting Blood Flow May Help Heart Bypass Patients
8. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
9. Study provides hope that some transplant patients could live free of antirejection drugs
10. Study provides hope that some transplant patients could live free of anti-rejection drugs
11. Longer ambulance journeys boost death risk for seriously ill patients
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: